M. J. Boers‐Sonderen

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Evalyn E.A.P. Mulder, Karlijn de Joode, Saskia Litière et al. · BMC Cancer · 2021 · 50 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

M Franken, B Leeneman, Maureen J.B. Aarts et al. · ESMO Open · 2021 · 39 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

Annelies H. Boekhout, Anne Rogiers, Katarzyna Jóźwiak et al. · Acta Oncologica · 2020 · 31 citations · Full text

Life Sciences, Immunology, Oncology +14

A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion

Sasja F. Mulder, M. J. Boers‐Sonderen, Erik H.F.M. van der Heijden et al. · Targeted Oncology · 2014 · 16 citations

Pharmacy, Oncology, Pharmacotherapy +11

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry

A. Özkan, Ellen Kapiteijn, Frederiek van den Bos et al. · European Journal of Cancer · 2024 · 11 citations · Full text

Medicine, Geriatric Medicine, Oncology +17